Clinical Trials
236 trialsUmbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for Hematological Diseases
Masonic Cancer Center, University of Minnesota
VTX002 Versus Placebo for the Treatment of Moderately to Severely Active Ulcerative Colitis
Oppilan Pharma Ltd
Decision Making Tool for Firearm Storage
University of Washington
Tazemetostat and Venetoclax in Relapsed/Refractory Non-Hodgkin Lymphoma
Weill Medical College of Cornell University
Study of VAY736 as Single Agent and in Combination With Select Antineoplastic Agents in Patients With Non-Hodgkin Lymphoma
Novartis
A Study of Voruciclib Alone or in Combination With Venetoclax in Subjects With B-Cell Malignancies or AML
MEI Pharma, Inc.
A Study to Evaluate the Safety and Preliminary Efficacy of ATA3219 in Participants With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
Atara Biotherapeutics
Umbralisib and Rituximab as Initial Therapy for Patients With Follicular Lymphoma and Marginal Zone Lymphoma
Massachusetts General Hospital
ELiPSE-1
Century Therapeutics, Inc.
Event-Related Potential (ERP) Components in Clinical Diagnosis
Boston University
EEPAB2
Assistance Publique - Hôpitaux de Paris
Pembrolizumab in Untreated B-Cell Non-Hodgkin Lymphoproliferative Diseases
University of Washington
A Study of bbT369 in Relapsed and/or Refractory B Cell Non-Hodgkin's Lymphoma (NHL)
Regeneron Pharmaceuticals
Genetically Engineered Cells (EGFRt/19-28z/IL-12 CAR T Cells) for the Treatment of Relapsed or Refractory CD19+ Hematologic Malignancies
Roswell Park Cancer Institute
Pembrolizumab With Rituximab or Obinutuzumab in Treating Patients With Relapsed or Refractory Follicular Lymphoma or Diffuse Large B Cell Lymphoma
University of Washington
Study to Evaluate the Clinical Activity and Safety of Oral NX-13 in Moderate to Severe Ulcerative Colitis
AbbVie
GLEAN-1
Adicet Therapeutics
Ibrutinib for Patients With Follicular Lymphoma Without Complete Response to Initial Chemoimmunotherapy
Memorial Sloan Kettering Cancer Center
Lenalidomide and Rituximab in Treating Patients With Non-Hodgkin Lymphoma
University of California, Davis
Connect® Lymphoma Disease Registry: A US-Based Prospective Observational Cohort Study
Celgene
Study of Copanlisib and Ketogenic Diet
Columbia University
Rituximab + Immunotherapy in Follicular Lymphoma
Dana-Farber Cancer Institute
An Efficacy and Safety Proof of Concept Study of Daratumumab in Relapsed/Refractory Mantle Cell Lymphoma, Diffuse Large B-Cell Lymphoma, and Follicular Lymphoma
Janssen Research & Development, LLC
Study of a Triple Combination Therapy, DTRM-555, in Patients With R/R CLL or R/R Non-Hodgkin's Lymphomas
Zhejiang DTRM Biopharma
Zandelisib (ME-401) in Subjects With Follicular Lymphoma or Marginal Zone Lymphoma After Failure of Two or More Prior Therapies (TIDAL)
MEI Pharma, Inc.
Efficacy and Safety Study of Ammonul® in Patients With Grade 3 or 4 Hepatic Encephalopathy
Amgen
GAUDEALIS
Fondazione Italiana Linfomi - ETS
Phase 3 Study of Zandelisib (ME-401) in Combination With Rituximab in Patients With iNHL - (COASTAL)
MEI Pharma, Inc.
First-in-Human (FIH) Trial of GEN3009 in Subjects With Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas
Genmab
An Open-Label, Multicenter Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab in Combination With Tiragolumab With or Without Atezolizumab in Participants With B-Cell Non-Hodgkin Lymphoma
Hoffmann-La Roche
Polatuzumab Vedotin, Venetoclax, and Rituximab and Hyaluronidase Human for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma
Academic and Community Cancer Research United
2002
Xenikos
Romidepsin Plus Oral 5-Azacitidine in Relapsed/Refractory Lymphoid Malignancies
Columbia University
Study of TG-1801 Alone or in Combination With Ublituximab in Subjects With B-Cell Lymphoma or Chronic Lymphocytic Leukemia
TG Therapeutics, Inc.
A Study of Imvotamab Monotherapy and in Combination in Subjects With Relapsed/Refractory Non-Hodgkin Lymphoma
IGM Biosciences, Inc.
A Study of MS-553 in Patients With Relapsed or Refractory B-cell Lymphoma
MingSight Pharmaceuticals, Inc
GEMHDM2014
AHS Cancer Control Alberta
QUILT-3.002: N-803 in Patients With Relapse/Refractory iNHL in Conjunction With Rituximab
Altor BioScience
A Study of Varlilumab and IMA950 Vaccine Plus Poly-ICLC in Patients With WHO Grade II Low-Grade Glioma (LGG)
University of California, San Francisco
A Dose-Finding and Efficacy Study of Venetoclax, CC-486, and Obinutuzumab in Follicular Lymphoma
University of Chicago
SYMPHONY-2, A Trial to Examine Combination of Tazemetostat With Rituximab in Subjects With Relapsed/Refractory Follicular Lymphoma
Ipsen
Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 562 in Subjects With r/r Diffuse Large B-cell Lymphoma, Mantle Cell Lymphoma, or Follicular Lymphoma
Amgen
Rituximab With or Without Ibrutinib for Patients With Advanced Follicular Lymphoma
Swiss Cancer Institute
Idelalisib Post Allogeneic Hematopoietic Stem Cell Transplant (HSCT) in B Cell Derived Malignancies
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Study of Mocetinostat in Selected Patients With Mutations of Acetyltransferase Genes in Relapsed and Refractory Diffuse Large B-Cell Lymphoma and Follicular Lymphoma
Memorial Sloan Kettering Cancer Center
Study of BN301, an Anti-CD74 Antibody Drug Conjugate, in Patients With Advanced B-Cell Malignancies
BioNova Pharmaceuticals (Shanghai) LTD.
PRT1419 as Monotherapy or in Combination With Azacitidine or Venetoclax in R/R Myeloid or B-cell Malignancies
Prelude Therapeutics
Ipilimumab and Local Radiation for Selected Solid Tumors
Stanford University
LOTIS-6
ADC Therapeutics S.A.
DYNAMO + R
SecuraBio